Ibrutinib-associated osteonecrosis of the jaw Journal Article

  


Authors: Singh, A.; Na, S.; Huryn, J. M.; Estilo, C. L.; Horwitz, S.; Yom, S. K.
Article Title: Ibrutinib-associated osteonecrosis of the jaw
Abstract: Ibrutinib is an FDA-approved first-generation oral Bruton tyrosine kinase (BTK) inhibitor that has been used in the treatment of patients with chronic lymphocytic leukemia (CLL). Ibrutinib has well-described side effects that limits its use such as, increased risk of atrial fibrillation, hypertension, and hemorrhage. However, oral toxicity associated with ibrutinib has not been reported. This case report describes spontaneous medication related osteonecrosis of jaw (MRONJ) in a 72-year-old male patient with CLL likely following prolonged treatment with ibrutinib © 2024 The Authors
Keywords: tyrosine kinase inhibitor; osteonecrosis; ibrutinib; medication related osteonecrosis of the jaw
Journal Title: Oral Oncology Reports
Volume: 9
ISSN: 2772-9060
Publisher: Elsevier Ltd  
Date Published: 2024-03-01
Start Page: 100228
Language: English
DOI: 10.1016/j.oor.2024.100228
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85188205526&doi=10.1016%2fj.oor.2024.100228&partnerID=40&md5=c164bfdf95c5ede8b1c65a224a03218c
Notes: Letter MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PDF -- MSK corresponding author is SaeHee Yom -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Joseph M Huryn
    108 Huryn
  2. Cherry Estilo
    93 Estilo
  3. Steven M Horwitz
    645 Horwitz
  4. SaeHee Kim Yom
    42 Yom
  5. Annu Singh
    22 Singh
  6. Sion Na
    1 Na
Related MSK Work